

# LifeWatch

## Maintaining the rhythm

A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company's fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch's new strategic direction.

## Adding another beat

The recent FDA 510k approval and grant of CE mark in Europe for the MCT 1-lead patch enables LifeWatch to commercialise a cardiac monitoring device that is lighter, more discreet and more comfortable than traditional devices. This should improve patient compliance and provide better-quality monitoring data, to enable physicians and patients to make more informed decisions over ongoing care. Further product approval and launches are expected as the year progresses, which is key to maintaining an edge in an increasingly competitive digital heath market.

## Strategic broadening of product portfolio

The agreement with AliveCor to use its FDA-approved Mobile ECG technology will enhance LifeWatch's cardiac portfolio offering. The AliveCor technology attaches to a mobile phone, is quick (records an ECG in just 30 seconds), is easy to use (readings from finger or chest), and can detect atrial fibrillation in screening patients over 65 years-old at primary care clinics and pharmacies in the US.

## Waking up to new indications

Suspending its home sleep testing services and purchasing FlexLife Health demonstrate a willingness to cut underperforming areas while investing in new areas for growth. While LifeWatch still sees value in home sleep testing, FlexLife appears more complementary to the cardiac monitoring franchise with its remote coagulation management systems (AMS). Coagulation monitoring is vital for patients taking anti-coagulants such as warfarin (risk of bleeding/clotting if dose too high/low), while warfarin is often used to treat atrial fibrillation, the main cause of a clinical arrhythmia detectable via LifeWatch's cardiac monitoring devices.

## Valuation: 2.2x EV/sales belies growth prospects


An FY14 EV/sales ratio of just 2.2x seems at odds with the +9% H115 growth rate and the company's FY15 guidance of 10-15% revenue growth. FY16 will benefit from an 8% Medicare price increase, resulting in an estimated +\$3.4m in revenues.

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	80.1	4.1	(0.03)	0.0	N/A	N/A
12/13	91.1	(2.5)	0.22	0.0	73.9	N/A
12/14	98.5	(0.2)	(0.21)	0.0	N/A	N/A

### **Medical technology**

Price Market cap CHF16.25 CHF219m CHF1.0/US\$

### Share price graph



#### **Share details**

Code	LIFE
Shares in issue	13.5m
Net cash (\$m) at 30 June 2015	1.2

#### **Business description**

LifeWatch, headquartered in Switzerland and listed on SIX, specialises in advanced digital health systems and wireless remote diagnostic patient monitoring services (eg ambulatory cardiac telemetry, ACT). Its primary operations are in the US, Switzerland and Israel.

#### Bull

- Established US business with cardiac monitoring unit outperforming the market.
- Well positioned to benefit from expected advance of digital health solutions.
- Turnaround continues with strong H115 revenues and earnings (+9.1% sales growth to \$52.5m).

### Bear

- Digital health is a highly competitive and rapidly evolving market.
- Relatively low-margin business (7% operating margin in H115); challenge to grow margins against need to reinvest.
- Modest net cash position limits capacity/flexibility to strike transformational deals.

### **Analysts**

Christian Glennie +44 (0)20 3077 5727

Daniel Wilkinson +44 (0)20 3681 5734

healthcare@edisongroup.com

LifeWatch is a research client of Edison Investment Research Limited



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (<a href="https://www.fsa.gov.uk/register/firmBasicDetails.do/sid=181584">www.fsa.gov.uk/register/firmBasicDetails.do/sid=181584</a>). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [4794244]. <a href="https://www.edisongroup.com">www.edisongroup.com</a>

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by LifeWatch and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research of Edison at the time of publication. The securities and the Research may not be eligible for sale in all jurisdictions or to certain categories of investment as it is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US rolls and Exchange Commission. Edison US relies upon the "publishers" exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation or indicoment and babitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the indep

London Stock Exchange Group companies and is used by FTSE International Limited under licenses. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.